Literature DB >> 15223166

Screening for mutations in the SRY gene in patients with mixed gonadal dysgenesis or with Turner syndrome and Y mosaicism.

Patricia Canto1, Norma Galicia, Daniela Söderlund, Irineo Escudero, Juan Pablo Méndez.   

Abstract

OBJECTIVE: To investigate the presence of mutations in the open reading frame (ORF), as well as on the 5' and 3', flanking regions of the SRY gene in patients with mixed gonadal dysgenesis (MGD) or with Turner syndrome (TS) and Y mosaicism. STUDY
DESIGN: We studied 13 patients with MGD and three patients with TS and Y mosaicism. DNA was isolated from blood leukocytes for subsequent polymerase chain reaction (PCR) and direct sequencing were performed in the ORF, as well as from the 5' and 3' flanking regions of the SRY gene.
RESULTS: No mutations were present in any of the patients studied.
CONCLUSION: The absence of mutations in these regions indicated that mutations were an unlikely cause of MGD or TS with Y mosaicism and suggested that there are others genes playing an important role in sex development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15223166     DOI: 10.1016/j.ejogrb.2003.10.035

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  2 in total

1.  The clinical and genetic heterogeneity of mixed gonadal dysgenesis: does "disorders of sexual development (DSD)" classification based on new Chicago consensus cover all sex chromosome DSD?

Authors:  Gönül Ocal; Merih Berberoğlu; Zeynep Sıklar; Hatice Ilgın Ruhi; Ajlan Tükün; Emine Camtosun; Senay Savaş Erdeve; Bülent Hacıhamdioğlu; Suat Fitöz
Journal:  Eur J Pediatr       Date:  2012-05-30       Impact factor: 3.183

2.  Turner Syndrome with Y Chromosome: Spontaneous Thelarche, Menarche, and Risk of Malignancy.

Authors:  Elizabeth Dabrowski; Emilie K Johnson; Vrunda Patel; YeoChing Hsu; Shanlee Davis; Allison L Goetsch; Reema Habiby; Wendy J Brickman; Courtney Finlayson
Journal:  J Pediatr Adolesc Gynecol       Date:  2019-08-26       Impact factor: 1.814

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.